STAAR Surgical stock gets a USD 50 million buyback authorization

Published on 10/05/2026 at 12:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

STAAR Surgical stock was last at USD 22.47 on October 2, while its board authorized a USD 50 million buyback. Second-quarter revenue rose 111.0 percent year over year.

STAA, US8523123052, Illustration mit AI erstellt.

STAAR Surgical (ISIN US8523123052) stock was last at USD 22.47 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with a daily gain of 0.40 percent. The company had just authorized a USD 50 million share repurchase program on September 24, 2026, giving the stock a capital-allocation catalyst while investors weigh the strength of its China-led recovery.

Buyback puts cash to work

According to STAAR Surgical on September 24, 2026, the board authorized purchases of up to USD 50 million of common stock over the next 12 months. The company said the program may use open-market purchases, private transactions, block purchases or Rule 10b5-1 plans.

The authorization is backed by a balance sheet that included USD 181.5 million in cash, cash equivalents and available-for-sale investments as of July 3, 2026, alongside no outstanding debt, according to STAAR Surgical. The planned purchases therefore connect the recent profit recovery with a more active use of corporate liquidity.

Q2 revenue more than doubles

STAAR Surgical reported USD 93.5 million in second-quarter 2026 revenue for the period ended July 3, up 111.0 percent from the prior-year quarter. The company also swung to USD 8.1 million of net income, or USD 0.16 in diluted earnings per share, from a USD 16.8 million net loss and a USD 0.34 loss per share a year earlier, according to StockTitan.

China generated USD 52.3 million of second-quarter sales, while revenue outside China reached USD 41.2 million, up 6.0 percent year over year, according to the same company filing carried by StockTitan. That split matters because the recovery remains heavily tied to China even as the broader business returns to profitability.

Analysts remain measured

Stifel upgraded STAAR Surgical to Buy from Hold on September 29, 2026, and raised its price target to USD 31 from USD 28, citing a possible shift toward higher-priced EVO+ lenses in China and easier comparisons elsewhere, Investing.com reported. The new target is 38.0 percent above the October 2 price of USD 22.47.

The wider view is less bullish. MarketBeat lists a Hold consensus from 13 analysts, with an average target of USD 28.45, a high target of USD 37.00 and a low target of USD 13.00. The average target stands 26.6 percent above the October 2 price, leaving the market focused on whether China growth can translate into a broader and more durable earnings base.

STAA stays below its yearly high

STAAR Surgical was last at USD 22.47 on Nasdaq on October 2, 2026 at 4:00 p.m. ET. Its 52-week range was USD 15.59 to USD 35.87, while market capitalization stood at USD 1.1 billion and volume reached 640,038 shares on that session.